|
1
|
Jeon S and Lee WK: Intravitreal
bevacizumab increases intraocular interleukin-6 levels at 1 day
after injection in patients with proliferative diabetic
retinopathy. Cytokine. 60:535–539. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ambresin A, Strueven V and Pournaras JA:
Painless indirect argon laser in high risk proliferative diabetic
retinopathy. Klin Monbl Augenheilkd. 232:509–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ribeiro L, Bandello F, Tejerina AN,
Vujosevic S, Varano M, Egan C, Sivaprasad S, Menon G, Massin P,
Verbraak FD, et al: Characterization of retinal disease progression
in a 1-year longitudinal study of eyes with mild nonproliferative
retinopathy in diabetes type 2. Invest Ophthalmol Vis Sci.
56:5698–5705. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mansberger SL, Sheppler C, Barker G,
Gardiner SK, Demirel S, Wooten K and Becker TM: Long-term
comparative effectiveness of telemedicine in providing diabetic
retinopathy screening examinations: A randomized clinical trial.
JAMA Ophthalmol. 133:518–525. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qing S, Yuan S, Yun C, Hui H, Mao P, Wen
F, Ding Y and Liu Q: Serum miRNA biomarkers serve as a fingerprint
for proliferative diabetic retinopathy. Cell Physiol Biochem.
34:1733–1740. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zampetaki A, Willeit P, Burr S, Yin X,
Langley SR, Kiechl S, Klein R, Rossing P, Chaturvedi N and Mayr M:
Angiogenic microRNAs linked to incidence and progression of
diabetic retinopathy in type 1 diabetes. Diabetes. 65:216–227.
2016.PubMed/NCBI
|
|
7
|
Mohamed QA, Fletcher EC and Buckle M:
Diabetic retinopathy: Intravitreal vascular endothelial growth
factor inhibitors for diabetic macular oedema. BMJ Clin Evid.
2016:pii: 0702. 2016.PubMed/NCBI
|
|
8
|
Scott IU, Jackson GR, Quillen DA, Larsen
M, Klein R, Liao J, Holfort S, Munch IC and Gardner TW: Effect of
doxycycline vs placebo on retinal function and diabetic retinopathy
progression in patients with severe nonproliferative or
non-high-risk proliferative diabetic retinopathy: A randomized
clinical trial. JAMA Ophthalmol. 132:535–543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kaštelan S, Tomić M, Antunica Gverović A,
Salopek Rabatić J and Ljubić S: Inflammation and pharmacological
treatment in diabetic retinopathy. Mediators Inflamm.
2013:2131302013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen ZH, Wu YF, Wang PL, Wu YP, Li ZY,
Zhao Y, Zhou JS, Zhu C, Cao C, Mao YY, et al: Autophagy is
essential for ultrafine particle-induced inflammation and mucus
hyperproduction in airway epithelium. Autophagy. 12:297–311. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qin WD, Liu GL, Wang J, Wang H, Zhang JN,
Zhang F, Ma Y, Ji XY, Li C and Zhang MX: Poly(ADP-ribose)
polymerase 1 inhibition protects cardiomyocytes from inflammation
and apoptosis in diabetic cardiomyopathy. Oncotarget.
7:35618–35631. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang X, Sun CY, Zhang YB, Guo HZ, Feng
XX, Peng SZ, Yuan J, Zheng RB, Chen WP, Su ZR and Huang XD: Kegan
Liyan oral liquid ameliorates lipopolysaccharide-induced acute lung
injury through inhibition of TLR4-mediated NF-κB signaling pathway
and MMP-9 expression. J Ethnopharmacol. 186:91–102. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singh K, Kant S, Singh VK, Agrawal NK,
Gupta SK and Singh K: Toll-like receptor 4 polymorphisms and their
haplotypes modulate the risk of developing diabetic retinopathy in
type 2 diabetes patients. Mol Vis. 20:704–713. 2014.PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bressler SB, Almukhtar T, Aiello LP,
Bressler NM, Ferris FL III, Glassman AR and Greven CM: Diabetic
Retinopathy Clinical Research Network: Green or yellow laser
treatment for diabetic macular edema: Exploratory assessment within
the diabetic retinopathy clinical research network. Retina.
33:2080–2088. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin WJ and Yeh WC: Implication of
Toll-like receptor and tumor necrosis factor alpha signaling in
septic shock. Shock. 24:206–209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen XL, Zhang XD, Li YY, Chen XM, Tang DR
and Ran RJ: Involvement of HMGB1 mediated signalling pathway in
diabetic retinopathy: Evidence from type 2 diabetic rats and
ARPE-19 cells under diabetic condition. Br J Ophthalmol.
97:1598–1603. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rajamani U and Jialal I: Hyperglycemia
induces Toll-like receptor-2 and −4 expression and activity in
human microvascular retinal endothelial cells: Implications for
diabetic retinopathy. J Diabetes Res. 2014:7909022014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Berger EA, Carion TW, Jiang Y, Liu L,
Chahine A, Walker RJ and Steinle JJ: β-Adrenergic receptor agonist,
compound 49b, inhibits TLR4 signaling pathway in diabetic retina.
Immunol Cell Biol. 94:656–661. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lv YN, Ou-Yang AJ and Fu LS: MicroRNA-27a
negatively modulates the inflammatory response in
lipopolysaccharide-stimulated microglia by targeting TLR4 and
IRAK4. Cell Mol Neurobiol. 37:195–210. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu H and Chen M: Targeting the complement
system for the management of retinal inflammatory and degenerative
diseases. Eur J Pharmacol. 787:94–104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wohlfart P, Lin J, Dietrich N, Kannt A,
Elvert R, Herling AW and Hammes HP: Expression patterning reveals
retinal inflammation as a minor factor in experimental retinopathy
of ZDF rats. Acta Diabetol. 51:553–558. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jennewein C, von Knethen A, Schmid T and
Brune B: MicroRNA-27b contributes to lipopolysaccharide-mediated
peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA
destabilization. J Biol Chem. 285:11846–11853. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong Z, Tao X, Fu X, Wang H, Wang D and
Zhang T: Protective effects of Purendan superfine powder on retinal
neuron apoptosis in a rat model of type 2 diabetes mellitus. Neural
Regen Res. 7:202–206. 2012.PubMed/NCBI
|
|
25
|
Kowluru RA: Diabetic retinopathy:
Mitochondrial dysfunction and retinal capillary cell death.
Antioxid Redox Signal. 7:1581–1587. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khalfaoui T, Basora N and Ouertani-Meddeb
A: Apoptotic factors (Bcl-2 and Bax) and diabetic retinopathy in
type 2 diabetes. J Mol Histol. 41:143–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kern TS, Du Y, Miller CM, Hatala DA and
Levin LA: Overexpression of Bcl-2 in vascular endothelium inhibits
the microvascular lesions of diabetic retinopathy. Am J Pathol.
176:2550–2558. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fan Y, Liu K, Wang Q, Ruan Y, Zhang Y and
Ye W: Exendin-4 protects retinal cells from early diabetes in
Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax
ratios and reducing reactive gliosis. Mol Vis. 20:1557–1568.
2014.PubMed/NCBI
|
|
29
|
Tian Y, Fu S, Qiu GB, Xu ZM, Liu N, Zhang
XW, Chen S, Wang Y, Sun KL and Fu WN: MicroRNA-27a promotes
proliferation and suppresses apoptosis by targeting PLK2 in
laryngeal carcinoma. BMC Cancer. 14:6782014. View Article : Google Scholar : PubMed/NCBI
|
